Neoadjuvant Anti-PD-1 Antibody (Toripalimab) or Combined With Chemotherapy in HNSCC Patients

Inclusion Criteria: * Confirmed pathologic or cytologic diagnosis of squamous cell carcinoma of head and neck; * Resectable or potentially resectable lesion; * ECOG PS 0-1; * Age \>18 years old; * At least one target lesion according to RECIST 1.1; * Proper function of the cardiovascular system, liver, kidney and bone marrow for receiving chemotherapy and surgery; Exclusion Criteria: * Distant metastasis; * Second malignancy within 5 years; * Nasopharyngeal carcinoma; * Active autoimmune diseases; * HIV infected; * Required prednisone dose \>=10mg daily; * Heart attack within 6 months; * Stroke within 6 months; * Other conditions that investigators consider the patients are not suitable for PD-1antibody;